Contineum Therapeutics (CTNM) Q2 2026 earnings summary

Executive summary

• Clinical-stage biopharma focused on small molecule therapies for inflammatory and fibrotic diseases, with lead assets PIPE-791 (IPF, chronic pain) and PIPE-307 (depression, partnered with J&J).

• PIPE-791 advanced to a global Phase 2 PROPEL-IPF trial with over 55 sites in eight countries and showed positive Phase 1b data in chronic pain; PIPE-307 Phase 2 MOONLIGHT-1 trial for depression completed enrollment by J&J.

• Streamlined discovery programs to focus on inflammatory and fibrotic diseases, resulting in a limited workforce reduction, including departure of Chief Scientific Officer.

• No product revenue; operations funded by equity offerings and a $50M upfront from J&J.

Financial highlights

• Net loss of $15.2M for Q2 2026, improved from $16.0M in Q2 2025; net loss of $29.6M for H1 2026, improved from $32.0M in H1 2025.

• Operating expenses decreased to $17.4M in Q2 2026 from $17.9M in Q2 2025, mainly due to lower R&D costs.

• Research and development expenses were $12.7M, down 10% year-over-year due to lower costs for PIPE-307 and PIPE-791 chronic pain trials.

• General and administrative expenses rose 23% year-over-year to $4.7M, mainly from higher stock-based compensation.

• Cash, cash equivalents, and marketable securities totaled $236.6M as of June 30, 2026.

Outlook and guidance

• Cash runway projected through mid-2029, approximately one year past estimated completion of the IPF trial.

• Existing cash and investments expected to fund operations for at least 12 months from the report date.

• Operating expenses projected to increase as clinical programs advance and headcount grows.

• Future funding may come from equity, debt, or strategic partnerships; inability to secure funding could delay development.

• Focused on advancing highest potential clinical programs, particularly PIPE-791 for IPF.